Clinical Trial Search

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale

Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants

Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants

Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: Uric Acid Level — 8.23; 8.03 mg/dL

Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356

Primary: Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL — 68 Subjects

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 31; 52; 9; 15 Participants

Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472

Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001

Primary: Percentage of Participants With an sUA Level That is < 5.0 mg/dL — 82.5; 77.8 Percentage of participants

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares

Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5

Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298

Primary: Responders — 17; 28; 9 Participants

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale

Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001

Primary: Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. — 80.8; 87.0; 46.0 percentage of subjects

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants

Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants

Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares

Primary: Change From Baseline to Month 12 in Serum Creatinine — 2.52; 2.10; 2.22; 0.19 mg/dL — p=0.459

Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…